Ad-Manum Finance Regulatory Approval

Ad-Manum Finance Q2 FY27 Results: Net Profit ₹2.8 Cr, Up 133.3% YoY

Ad-Manum Finance Ltd reported revenue from operations of ₹4.9 Cr (+88.5% YoY) and net profit of ₹2.8 Cr (+133.3% YoY) for Q2 FY27.

Key figure

Net profit ₹2.8 Cr · +133.3% YoY

Ad-Manum Finance Financial Results

Ad-Manum Finance's board approved unaudited results for the quarter and half-year ended 30 September 2026. The results figures are not included in this filing.

Ad-Manum Finance Board Meeting Date

Ad-Manum Finance Limited scheduled a board meeting for October 26, 2026, to consider and approve the standalone unaudited financial results for the half year ended September 2026.

Ad-Manum Finance Other Announcement

The company has filed its quarterly shareholding pattern for the period ended 30th September 2026 as per SEBI regulations.

Ad-Manum Finance Management Change

Ad-Manum Finance Limited's shareholders confirmed the appointment of Mr. Pramod Kishore Shrivastava as Chairman and Non-Executive Director at the 40th Annual General Meeting.

Ad-Manum Finance Annual General Meeting

Ad-Manum Finance Limited submitted the proceedings of its 40th Annual General Meeting held on September 9, 2026. The meeting concluded successfully in hybrid mode.

RNFI Services Regulatory Approval

RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr